With GLP-1 drugs gaining widespread popularity and media coverage, the coming years will see unprecedented attention directed toward obesity drug development. This momentum presents a new challenge: next-generation therapeutics—amylin analogues, multi-target agonists, and gene and nucleic acid therapies—are far more complex in their mechanisms, and traditional preclinical platforms will struggle to deliver predictive accuracy, according to a press release from Protheragen Obesity.
Traditional diet-induced obesity (DIO) models carry inherent limitations. Classical evaluation systems focus heavily on macroscopic endpoints, particularly changes in body weight and food intake, while overlooking critical pharmacodynamic dimensions such as body composition, energy metabolic homeostasis, dynamic changes in insulin sensitivity, and target organ histopathology including hepatic steatosis and adipose tissue macrophage infiltration. This likely contributes to the high attrition rate of compounds that perform well in preclinical studies but fail in clinical trials due to efficacy or safety concerns.
Concurrently, the maturation of CRISPR/Cas9 gene editing technology is reshaping model development. Gene editing-based obesity models now enable precise recapitulation of human obesity-associated genetic mutations in the LEP, LEPR, and MC4R pathways, providing previously unavailable validation platforms. Humanized models support antibody target validation, while conventional knockout/knock-in models enable mechanistic studies of target biology. The model selection paradigm has evolved from availability to precision matching.
To address diverse requirements across different development stages and target types, Protheragen Obesity has established a tiered, customizable obesity models technical system. This includes in vitro cell models such as the 3T3-L1 preadipocyte differentiation system and primary adipocyte and hepatocyte co-culture platforms for high-throughput screening; gene-edited models with single/multi-gene mutations, transgenic, and humanized replacement models for antibody and gene therapy vector validation; diet-induced models using high-fat, high-sugar, and high-fat combined with low-dose STZ for obesity with type 2 diabetes comorbidities; and chemically and surgically induced models like hypothalamic injury and ovariectomy models for specific mechanistic questions.
Each model is equipped with a comprehensive metabolic phenotyping system covering DEXA/MRI body composition monitoring, indirect calorimetry, glucose and insulin tolerance testing, and histopathological examination, ensuring data traceability and cross-experimental comparability.
Protheragen Obesity operates under a GLP-compliant quality management system. For DIO studies, which typically run 8 to 16 weeks, the model induction success rate exceeds 90%. For gene-edited models, the company provides comprehensive genotyping reports, copy number and integration site analysis, and germline transmission validation data. All study reports meet FDA and NMPA requirements for IND-enabling pharmacology submissions.
The company offers three collaboration models: full-service outsourcing from model construction to data analysis, modular services where clients purchase specific components, and co-development partnerships for joint investment in novel model development. Every engagement begins with a consultation phase, where the technical team works directly with client researchers to understand the molecular modality, mechanism of action, and regulatory pathway, then customizes the optimal model strategy.
With extensive experience in metabolic disease research, Protheragen Obesity has supported dozens of biopharmaceutical companies in completing obesity drug development programs from target validation to IND submission.
